Skip to main
BCYC

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 43%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that is developing innovative medicines called Bicycles, which are synthetic short peptides that can be used to target a variety of diseases. The company's initial focus is on oncology, with its lead product candidate, BT1718, showing promising results as a Bicycle Toxin Conjugate in clinical trials. Despite recent setbacks in its development plans, the company's strong financials and partnerships in the UK and US make it a promising investment opportunity.

Bears say

Bicycle Therapeutics is facing several challenges that contribute to a negative outlook, including potential difficulties in their ongoing Ph 3 trial design discussions with regulatory authorities and uncertainties surrounding the appropriate comparator arm for the trial. Additionally, the company's reliance on their lead product candidate, BT1718, and their focus on oncology indications with high unmet medical needs may lead to clinical and regulatory risk. There is also a potential for competition from larger biopharmaceutical companies with similar capabilities and next-generation Nectin-4 ADCs that could limit Bicycle Therapeutics' market share and pricing power.

BCYC has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 43% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 7 analysts, BCYC has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.